.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,786,390

« Back to Dashboard

Claims for Patent: 5,786,390

Title: Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
Abstract:The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.
Inventor(s): Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL)
Assignee: Teva Pharmaceutical Industries Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:08/470,161
Patent Claims: 1. A pharmaceutical composition which consists essentially of a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet.

3. The pharmaceutical composition of claim 2, wherein the therapeutically effective amount is an amount from about 0.1 mg to about 100 mg.

4. The pharmaceutical composition of claim 3, wherein the therapeutically effective amount is an amount from about 1 mg to about 10 mg.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution.

6. The pharmaceutical composition of claim 5, wherein the therapeutically effective amount is an amount from about 0.1 mg/ml to about 100 mg/ml per dosage unit.

7. The pharmaceutical composition of claim 6, wherein the therapeutically effective amount is an amount from about 1 mg/ml to about 10 mg/ml per dosage unit.

8. The pharmaceutical composition of claim 1, wherein the carrier is a gel and the pharmaceutical composition is a suppository.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt is a mesylate salt.

10. A pharmaceutical composition which consists essentially of a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of Levodopa, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, and the therapeutically effective amount of Levodopa is about 50 mg to about 250 mg.

12. The pharmaceutical composition of claim 10, wherein the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, and the therapeutically effective amount of Levodopa is about 50 mg to about 200 mg.

13. A pharmaceutical composition which consists essentially of a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of a decarboxylase inhibitor, and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, wherein the decarboxylase inhibitor is L-Carbidopa.

15. The pharmaceutical composition of claim 13, wherein the decarboxylase inhibitor is benserazide.

16. The pharmaceutical composition of claim 13, wherein the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, and the therapeutically effective amount of the decarboxylase inhibitor is about 10 mg to about 25 mg.

17. The pharmaceutical composition of claim 16, wherein the decarboxylase inhibitor is L-Carbidopa.

18. The pharmaceutical composition of claim 13, wherein the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, and the therapeutically effective amount of the decarboxylase inhibitor is about 12.5 mg to about 50 mg.

19. The pharmaceutical composition of claim 18, wherein the decarboxylase inhibitor is benserazide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc